Open AccessAnaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant
Author(s) -
Vishwanath Sathyanarayanan,
K. Lokesh,
K C Lakshmaiah,
K Govind Babu,
Lokanatha Dasappa,
M C Suresh Babu,
Clementina Rama Rao,
Premalata Chennagiri
Publication year - 2014
Publication title -
annals of saudi medicine/annals of saudi medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.373
H-Index - 44
eISSN - 0975-4466
pISSN - 0256-4947
DOI - 10.5144/0256-4947.2014.551
Subject(s) - anaplastic large cell lymphoma , medicine , breast implant , anaplastic lymphoma kinase , lumpectomy , lymphoma , vincristine , cd30 , oncology , cyclophosphamide , breast cancer , chemotherapy , mastectomy , surgery , implant , cancer , pleural effusion , malignant pleural effusion
Non-Hodgkin lymphoma of the breast is an uncommon entity accounting for approximately 0.5% of malignant breast neoplasms and around 3% of extranodal lymphomas. Most cases of anaplastic large cell lymphoma (ALCL) of the breast have been associated with breast implants, and a few ALCL aris.ing de novo in patients without breast implants have been reported. We report a case of a 19-year-old female who presented with a lump in the right breast of 3 months' duration. Examination revealed an Eastern Cooperative Oncology Group performance status of 2 and a 6.5 cm2 lump in the right breast. Lumpectomy revealed large neoplastic cells positive for CD30, EMA, CD5, and anaplastic lymphoma kinase (ALK), suggestive of anaplastic large cell lymphoma. The patient underwent lumpectomy followed by 6 cycles of anthracycline-based chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone 3 weekly. On follow up, this patient had an event-free survival of 23 months. We are reporting this case of ALCL (ALK positive) in a patient with no breast implant previously, and hence, it is of clinical importance.